Log In
BCIQ
Print this Print this
 

GDC-0919, NLG919, RG6078

  Manage Alerts
Collapse Summary General Information
Company NewLink Genetics Corp.
DescriptionOral small molecule inhibitor of indoleamine 2,3-dioxygenase (INDO; IDO)
Molecular Target Indoleamine 2,3-dioxygenase (INDO) (IDO)
Mechanism of ActionIndoleamine 2,3-dioxygenase (INDO) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat recurrent or advanced solid tumors
Regulatory Designation
PartnerGenentech Inc.;
Roche

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$150.0M

$1,000.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/20/2014

Undisclosed

$150.0M

$1,000.0M

Get a free BioCentury trial today